Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and MaxCyte, Inc., a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announce the signing of a strategic platform license.
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy ProgramsPublished on :
Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.
Ian is an industrial microbiologist and fermentation scientist specializing in process optimization and upstream modification of cell culture parameters for increased yield, viability, and productivity. Experienced with a variety of fermentation technologies, including hollow-fiber bioreactor systems, industrial stirred-tanks, and shake-flasks, Ian is excited to lend his background in cell culture to the SBI team.